Purulent wounds (including those infected with mixed microflora) in the first (purulent-necrotic) phase of the wound process.
active ingredients: 1 g of ointment contains chloramphenicol 10 mg, sulfadimethoxine 40 mg, methyluracil 40 mg, trimecaine 30 mg; excipients: polyethylene glycol 1500, polyethylene glycol 400.
Levosin Dosage form. Ointment.
The ointment is white with a yellowish tinge.
Pharmacotherapeutic group. Antibiotics in combination with chemotherapeutic agents. ATC code D06C.
Pharmacological properties. Levosin is a combined drug that has antimicrobial, anti-inflammatory (dehydrating), necrolytic and analgesic effect. Active against gram-positive and gram-negative microorganisms, as well as anaerobes. The water-soluble base of the ointment – polyethylene glycol – enhances and prolongs its antibacterial effect. The ointment easily penetrates glubo into tissues without damaging biological membranes, transporting chloramphenicol and sulfadimethoxine bound to polyethylene glycol. The ointment exhibits strong dehydrating properties, thereby helping to reduce perifocal edema and cleanse the wound from purulent-necrotic contents. The drug does not have a cumulative and local irritating effect.
Indications for use. Purulent wounds (including those infected with mixed microflora) in the first (purulent-necrotic) phase of the wound process.
Contraindications Individual hypersensitivity to the components of the drug, psoriasis, eczema, fungal skin lesions.
Appropriate safety precautions for use. The use of the drug can lead to skin sensitization, accompanied by the development of a hypersensitivity reaction with the further use of this drug externally or in the form of dosage forms of systemic action. In the presence of purulent or necrotic masses, the antibacterial effect of the drug remains. With prolonged (more than 1 month) use of the drug, it is necessary to monitor the state of the peripheral blood. Do not allow the ointment to come into contact with the eyes, mucous membranes.
Levosin Special warnings.
Application during pregnancy or lactation. Clinical experience with use during pregnancy or lactation is limited, so the use of the ointment is possible if the expected benefit to the mother, in the opinion of the doctor, outweighs the potential risk to the fetus / child.
The ability to influence the reaction rate when driving or operating other mechanisms. Does not affect.
Children. There is no data on the safety of the drug in children. Do not administer the drug to children.
Method of administration and dosage. Apply topically. Cover sterile napkins with ointment, with which to loosely fill the wound after its standard processing (mechanical removal of necrotic tissue, washing with hydrogen peroxide solution). It is possible to inject the drug into the purulent cavity through a catheter (drainage tube) using a syringe. In these cases, first warm up the drug to 35-36 ° C. Dressings should be done every day until the wound is completely cleansed.
External use of the drug in recommended doses does not cause overdose. With prolonged and frequent use of the ointment, the appearance and intensification of the described side reactions may occur. If side effects appear, you should stop using the ointment and consult a doctor. Further treatment is symptomatic.
When using the drug, allergic reactions may develop, including skin rashes, itching, dermatitis, burning sensation, hyperemia, angioedema, urticaria. In this case, the use of the ointment should be discontinued and a doctor should be consulted.
Interaction with other medicinal products. Simultaneous use with drugs that inhibit hematopoiesis (sulfonamides, cytostatics, pyrazoline derivatives) is undesirable.
2 years. Do not use after the expiration date printed on the package.
Store in its original packaging at temperatures between 8 ° C and 15 ° C. Keep out of the reach of children.
40 g of ointment in a tube. One tube in a cardboard box.
Vacation category. Over the counter.